Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DSE59Z
|
|||
| Drug Name |
pbi-shRNA STMN1
|
|||
| Drug Type |
Short hairpin RNA
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [1] | |
| Breast cancer [ICD-11: 2C60-2C65] | Investigative | [2] | ||
| Company |
Gradalis
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | STMN1 messenger RNA (STMN1 mRNA) | Target Info | Inhibitor | [3] |
| KEGG Pathway | MAPK signaling pathway | |||
| MicroRNAs in cancer | ||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| Panther Pathway | Cytoskeletal regulation by Rho GTPase | |||
| Pathway Interaction Database | Aurora B signaling | |||
| Signaling mediated by p38-gamma and p38-delta | ||||
| WikiPathways | EGF/EGFR Signaling Pathway | |||
| MAPK Signaling Pathway | ||||
| Retinoblastoma (RB) in Cancer | ||||
| Integrated Pancreatic Cancer Pathway | ||||
| Regulation of Microtubule Cytoskeleton | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01505153) Phase I Intratumoral Pbi-shRNA STMN1 LP in Advanced and/or Metastatic Cancer. U.S. National Institutes of Health. | |||
| REF 2 | The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954. | |||
| REF 3 | Clinical pipeline report, company report or official report of Gradalis. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.